Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy

In today's Pharmaceutical Executive Daily, a new West Health-Gallup survey finds that more than 82 million Americans have cut back on daily expenses to cover healthcare costs, the FDA expands the approved age indication for GSK's RSV vaccine Arexvy to adults aged 18 to 49 at increased risk, and a new commentary argues that agentic AI is positioned to fundamentally reshape commercial operations in life sciences.